COVID

AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial Trial met primary endpoint

2021-10-12

By Profiley AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial Trial met…